HMGB-1 (n = 88) | HMGB-1–weak (n = 42) | HMGB-1–strong (n = 46) | |
---|---|---|---|

Operation alone (n = 43) | 26 | 17 | |

Operation + NeoCRT (n = 45) | 16 | 29 | P = 0.04 (χ^{2} test) |

Calreticulin (n = 88) | Calreticulin–weak (n = 47) | Calreticulin–strong (n = 41) | |

Operation alone (n = 43) | 23 | 20 | |

Operation + NeoCRT (n = 45) | 24 | 21 | P = 0.85 (χ^{2} test) |

NOTE: HMGB1 and calreticulin expressions on tumors between patients with preoperative chemotherapy (*n* = 45, operation + NeoCRT) and without preoperative chemoradiotherapy (*n* = 43, operation alone) are shown.